Latest Pre-exposure prophylaxis Stories
A large-scale clinical trial evaluating whether daily use of an antiretroviral-containing oral tablet or vaginal gel can prevent HIV infection in women is being modified because an interim review found that the gel, an investigational microbicide, was not effective among study participants.
VOICE, an HIV prevention trial evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women – daily use of one of two different ARV tablets or of a vaginal gel – will be dropping one of the oral tablets from the study.
A large-scale clinical trial evaluating whether daily use of an oral tablet or vaginal gel containing antiretroviral drugs can prevent HIV infection in women is being modified because an interim review found that the study cannot show that one of the study products, oral tenofovir, marketed under the trade name Viread, is effective.
ATLANTA, Aug. 16, 2011 /PRNewswire-USNewswire/ -- Just months after an AIDS drug demonstrated reasonable efficacy in preventing HIV infection in controlled clinical trials, seven leading AIDS organizations are urging the U.S.
Flexible, agile and generous funding structures needed to ensure development and delivery of lifesaving new options for HIV prevention ROME, July 19, 2011 /PRNewswire-USNewswire/ -- In the last year, promising trial results and critical scientific breakthroughs have changed the HIV prevention landscape, providing new opportunities for both a broader response to the epidemic with new prevention options and broader clinical and laboratory agendas with new research targets.
A special press conference at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) will today feature a panel consisting of researchers from the CDC TDF2 study, the Partners PrEP Study and the HPTN 052 study.
- A woman chauffeur.
- A woman who operates an automobile.